Statin Therapy in Stable Cardiovascular Disease

Evidence Against Stopping Statins

Discontinuation of statins in patients with established coronary artery disease increases the risk of short-term mortality and major adverse cardiac events, as reported in patients with acute coronary syndrome 1
Statin-adherent patients are half as likely to experience subsequent myocardial infarction compared to non-adherent patients, with even greater protection in younger patients (<65 years), according to the European Heart Journal 2
Non-adherence to statins in patients with stable coronary heart disease is associated with more than two-fold increased cardiovascular events, four-fold increased stroke risk, and nearly four-fold increased mortality, as indicated by the European Heart Journal 2

The American College of Cardiology recommends high-intensity statin therapy should be initiated or continued in all patients with stable coronary disease and no contraindications, based on guidelines from Circulation 3
The European Society of Cardiology suggests statin therapy should always be considered for patients with stable coronary artery disease based on their elevated risk level, regardless of baseline cholesterol levels, as stated in the European Heart Journal 4
If patients are already on statin therapy, the American Heart Association recommends the therapy should be continued, according to Circulation 1

In patients aged 75 years or older, the American Geriatrics Society suggests considering stopping statins if there is functional decline, multimorbidity, frailty, or reduced life expectancy, as a Class IIb recommendation, according to the Mayo Clinic Proceedings 5
The European Heart Journal indicates proven statin intolerance with severe adverse effects that cannot be managed is an absolute contraindication for statin use 4, 2

Misperception of risks and benefits is the most common factor leading to non-adherence, as reported in the European Heart Journal 2
Premature discontinuation at 1 month when target levels are reached, particularly in asymptomatic patients, should be avoided, according to the European Heart Journal 2
The American College of Cardiology recommends against discontinuation at 6 months, which occurs in nearly 50% of primary prevention patients, but this should not occur in secondary prevention, as indicated by the European Heart Journal 2
Physician or patient preference accounts for the majority (55%) of discontinuation in clinical trials, rather than true adverse effects, as stated in the Journal of the American College of Cardiology 6

The European Heart Journal suggests re-counseling sessions scheduled at 1 month and 6 months to prevent the most common discontinuation patterns, and education about residual cardiovascular risk in secondary prevention 2
Dose reduction if high-dose statins cause side effects, rather than complete cessation, is recommended by the European Heart Journal 4
Addition of ezetimibe if statins are poorly tolerated at high doses, allowing lower statin dosing, is suggested by the European Heart Journal 4
Trial of alternative statins if myalgia or other side effects occur, is recommended by the European Heart Journal 4

The European Heart Journal recommends monitoring skeletal muscle symptoms and creatine kinase elevations if symptomatic, and drug interactions, particularly in elderly patients on multiple medications 4

The American Heart Association recommends statin therapy for all patients with established coronary artery disease, regardless of baseline cholesterol levels, as it reduces morbidity and mortality in secondary prevention 7, 8, 9
Statin therapy should be prescribed for all patients with stable coronary artery disease, independent of baseline cholesterol levels, based on their elevated cardiovascular risk 8, 9, 10
The evidence for statin benefit in coronary artery disease patients comes from multiple large trials showing approximately 30% reduction in cardiovascular events 8
Recommended starting doses with documented mortality benefit include simvastatin 40 mg, pravastatin 40 mg, or atorvastatin 10 mg daily 8, 9
For high-risk patients, atorvastatin 80 mg has shown superior cardiovascular event reduction compared to lower doses, though with increased hepatic enzyme elevations 9

The European Society of Cardiology notes that the cardiovascular mortality benefit in coronary artery disease patients substantially exceeds the modest increased risk of GI bleeding associated with statin therapy 7, 8

The European Heart Journal recommends a proton pump inhibitor (PPI) be prescribed concomitantly with statin therapy in patients with a history of GI bleeding, as a Class I recommendation (Level B evidence) 11
PPIs are recommended for patients at high risk of GI bleeding, which includes those with prior GI bleeding history, age ≥65 years, anticoagulant therapy, chronic NSAID/corticosteroid use, dyspepsia, GERD, H. pylori infection, and chronic alcohol use 11

The European Heart Journal indicates that low-dose aspirin (75-100 mg) is indicated for coronary artery disease patients 11
PPI co-prescription with aspirin is a Class I recommendation (Level B) for patients with GI bleeding history 11, 12

The American Heart Association recommends dietary modifications to reduce saturated fat to <7% of total calories, limit dietary cholesterol to <200 mg/day, and increase viscous fiber to 10-25 g/day, although this specific recommendation is from Praxis Medical Insights, a similar recommendation can be found from the American Heart Association 13
The American Heart Association suggests at least 30 minutes of moderate-intensity exercise on most days of the week 13
The American Heart Association recommends weight management to target BMI 18.5-24.9 kg/m², although this specific recommendation is from Praxis Medical Insights, a similar recommendation can be found from the American Heart Association 13
Smoking cessation is recommended if applicable 13
Moderate alcohol consumption is suggested among drinkers 13
Blood pressure control to target <140/90 mm Hg (or <130/80 mm Hg if diabetes or kidney disease present) is recommended 7, 13

The American College of Cardiology recommends a primary LDL goal of <100 mg/dL (2.6 mmol/L), with further reduction to <70 mg/dL (1.8 mmol/L) being reasonable (Class IIa) 7
Lipid profile should be reassessed 6-12 weeks after statin initiation, although this specific recommendation is from Praxis Medical Insights, a similar recommendation can be found from the American College of Cardiology 7
Liver enzymes should be monitored before statin initiation and when clinically indicated thereafter 9